Table 3

Interaction between maternal hyperglycaemia in pregnancy and periods (pre-IADPSG and post-IADPSG) on several neonatal outcomes

OutcomesP-value for interaction*†
Hospital death0.61
PDA required any treatment0.68
IVH or PVL0.19
CLD 280.61
ROP required any treatment0.12
  • *Calculated using multivariate logistic regression analysis with adjustment for maternal age, parity, mode of delivery, sex, antenatal steroid use, gestational week, SGA, Apgar score at 5 min.

  • †P value for interaction <0.1 is considered significant.

  • ‡Includes hospital death, NEC, PDA required any treatment, IVH or PVL, CLD 36 and ROP requiring any treatment.

  • CLD, chronic lung disease; IVH, intraventricular hemorrhage; NEC, necrotizing enterocolitis; PDA, patent ductus arteriosus; PVL, periventricular leukomalacia; RDS, respiratory distress syndrome; ROP, retinopathy of prematurity.